Does MEDP pay a dividend and is it safe?

Medpace Holdings Inc. (MEDP) offers a 0% cash dividend yield ($0.00 annualized) and 1.8% total shareholder yield including buybacks. Roarable rates its payout coverage as REINVESTING IN GROWTH + BUYBACKS.

Stock Ratings / Health Care / MEDP / dividends

CRL (64) ICLR (72) INCY (88) IQV (61) ⌘ Pro Terminal →

Medpace Holdings Inc. (MEDP) Dividend Safety Gauge & 10-Year DRIP Compounder

$648.14 -0.59% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $649.01

Medpace Holdings Inc. (MEDP) earns a Roarable Rating of B+ (Buy) with 77/100 RQD Confidence. High-quality cash engine (steady margins, 28% return on capital) with steady institutional support. The company’s underlying cash engine and institutional positioning keep the composite score in the Green Buy zone.

ROARABLE B+ • BUY Cap $18.24B

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on MEDP Below — or Connect Your Own ChatGPT / Claude

🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is MEDP stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

▼

As of 2026-11-03, Medpace Holdings Inc. (NASDAQ: MEDP) is rated B+ (Buy / BUY) by Roarable's 5-pillar RQD engine with a composite confidence score of 77/100 at a spot price of $648.14 (-0.59% 1D, market cap $18.24B). Pillar breakdown: Fundamental Cash Engine 19/20, Institutional 13F & Options Flow 15/20, SEC Balance-Sheet Forensics 16/20, FRED Macro Regime Fit 11/20, and Executive Insider Alignment 16/20. Across 1015 tracked Health Care issuers, MEDP ranks #24 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief

🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does MEDP compare to CRL and ICLR in the Health Care sector?

▼

Within the Health Care sector (Biotechnology: Commercial Physical & Biological Resarch), MEDP carries a Roarable B+ (77/100 RQD), trailing P/E of 42.0x, gross margin of —, and ROIC of 27.9%. By comparison, CRL (Charles River Laboratories International Inc.) holds a C grade (64/100 RQD, P/E N/A, ROIC 0.4%, cap $17.16B) and ICLR (ICON plc) posts a B grade (72/100 RQD, P/E 71.9x, ROIC 3.1%, cap $16.18B). Among the 5-stock peer group, INCY leads on earnings multiple (18.4x) while INCY leads on capital efficiency (42.4% ROIC).

✓ Pre-computed one-to-many AI Quant brief

🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for MEDP?

▼

Per MEDP's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001668397), Medpace Holdings Inc. generated $2.53B in revenue (+20.0% YoY), $451.1M in net income, and $681.9M in free cash flow against $1.98B in total assets and $682.4M in total debt. Key quantitative strengths: Strong cash generator (steady margins)—profits are backed by real money, not accounting tricks. Primary risk factors monitored: Priced at 42x earnings—high expectations leave less room for a lukewarm quarter. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief

🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

EXT / AFTER-HRS: $648.98 (+0.13%)🧬 Cannibal Buyback (-2.36% YoY Shares)⚙️ Cash Engine: 19/20 (A+) • 26.9% FCF Margin

Verify 90D Bucket Audit →

📊 Historical Track Record: Scores of 77/100 (B+) historically ranked in the Top 10% of excess returns over the next 90 days (+7.8% avg 90D alpha vs SPY • 70.3% hit rate).

Audit Bucket Track Record →

RQD QUANT TACHOMETERBUY • B+

3-of-3 JEV AI Jury Bullish

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw A- · Rk C+

Each axis scored 0–20

12M PRICE TARGET CONE+8.6% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for MEDP)Realized 20D OHLCV Swing Band: ±7.2%

Deterministic 5-Pillar Attribution (77/100 Composite)

🔍 WHY MEDP SCORES 77/100 (B+) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag

▲ #1 Bullish Driver: Cash Engine Quality+19/20 pts (25% of score)

SEC XBRL FY 2025 (10-K): 26.9% FCF Margin ($681.9M FCF) & 52% Gross Margin

▲ #2 Bullish Driver: SEC 10-K Forensic Risk+16/20 pts (21% of score)

Altman Z-Score 9.13 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 7/9

▼ #1 Drag / Risk Factor: Macro Regime Fit11/20 pts (-9 pt drag)

Macro rate sensitivity & RSI-14 (52.4) create a -9 pt regime headwind

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current

Q1 (-3Q)

Grade B-$616.63+7.4% Next Q

Q2 (-2Q)

Grade B$662.48+4.6% Next Q

Q3 (-1Q)

Grade B+$692.68-6.4% Next Q

Current

Grade B+$648.14+7.8% Hist 90D α

Trajectory: B- (69) → B+ (77)Full Audit →

⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)GIDEON ASHMERE // FORENSIC SHORT & KILL-SWITCH DOSSIER

⚔️ Adversarial Opposing Case: Why the MEDP Bull Thesis Could Fail

Gideon Ashmere Forensic Desk →

Even with a 77/100 (B+) score, MEDP faces multiple-compression risk if 42.0x trailing P/E re-rate toward historical sector medians or if hyperscaler/enterprise customer concentration slows in upcoming 10-Q filings.

⚠️ Forensic Kill-Switch #1

Priced at 42x earnings—high expectations leave less room for a lukewarm quarter.

⚠️ Forensic Kill-Switch #2

Dilution & Margin Drag: Cannibal Buyback (-2.36% YoY Shares) — any gross margin slip below 49.5% triggers an automatic RQD downgrade.

⚠️ Forensic Kill-Switch #3

Technical & Forensic Kill-Switch: A daily close below the 50D SMA ($622.17) or 200D SMA ($530.25) invalidates the momentum regime and cuts Target Base ($703.56) toward Bear Floor ($531.47).

🎲 LIVE PREDICTION MARKET ODDS TIED TO $MEDP• $2.4M Crowd Pool • Kalshi / Polymarket Composite

Contract: “MEDP Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”

YES 77%NO 23%Trade / Inspect Odds →

CASH DIVIDEND + BUYBACK YIELD

1.8% Total Yield

0% Cash ($0.00/yr) + 1.8% Buybacks

PAYOUT SAFETY SPEEDOMETER

74/100 • REINVESTING IN GROWTH + BUYBACKS

FREE CASH FLOW PAYOUT RATIO

0% (100% Reinvested)

Retains cash flow for R&D and share repurchases

INTERACTIVE DRIP & SHAREHOLDER-YIELD COMPOUNDER (12.8% EST. ANNUAL)

$10,000 Compounded Over 10 Years → $33,350

Est. Year-10 Shareholder Yield: $600/yr

Starting Investment: $10,000

Compounding Horizon: 10 Years

$11.3K

Yr 1

$12.7K

Yr 2

$14.4K

Yr 3

$16.2K

Yr 4

$18.3K

Yr 5

$20.6K

Yr 6

$23.2K

Yr 7

$26.2K

Yr 8

$29.6K

Yr 9

$33.3K

Yr 10

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher + Cash-Flow & Quality Compounder Desk

Cash-Fortress Compounders: Auditing Free Cash Flow & Yield Safety in MEDP & A-Rated Leaders

✓12-month Bull/Base/Bear fair-value walkthrough on MEDP and its top sector peer
✓Top Roarable A-Rated cash compounders with verified executive & 13F accumulation
✓Includes nightly RQD rating-change & forensic signal email alerts

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

MEDP // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +55.42%▲ ASCENDING CHANNEL

2026-11-03O $677.6H $677.6L $648.1C $648.1VOL 219.6K

RES: $700.8SUP: $600.5SMA50: $622.2SMA200: $530.3

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

MEDP Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 MEDP Butterfly Map → + Track MEDP →

Share Count & Dilution Monitor

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle

31.7%/yr Implied 5Y Growth

vs. +20.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger

No active Ellis Vennor swing setup published on MEDP today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for MEDP. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for MEDP today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (MEDP)

Health Care Rank #24 of 1015 ⚔️ CRL vs MEDP Full Matrix →

1. Head-to-Head Health Care Peer Comparison (MEDP vs. CRL, ICLR, INCY, IQV)

Industry: Biotechnology: Commercial Physical & Biological Resarch (12 Tracked Issuers)

Across 1015 tracked Health Care securities in the Roarable RQD universe, Medpace Holdings Inc. (MEDP) ranks #24 by composite RQD confidence (77/100, grade B+) and #71 by equity capitalization ($18.24B). Within this direct 5-issuer industry benchmark cohort, INCY leads on earnings valuation at 18.4x trailing P/E, while INCY leads on capital efficiency and profitability with 42.4% ROIC and 92.8% gross margin. INCY currently holds the highest overall quantitative score in the immediate peer group at 88/100 (A) compared with MEDP at 77/100 (B+).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
MEDP ACTIVE Medpace Holdings Inc.	B+	77/100	42.0x	—	27.9%	-0.59%	$18.24B	Benchmark Subject
CRL Charles River Laboratories International Inc.	C	64/100	—	—	0.4%	-5.81%	$17.16B	/crl-vs-medp →
ICLR ICON plc	B	72/100	71.9x	—	3.1%	-2.94%	$16.18B	/iclr-vs-medp →
INCY Incyte Corp.	A	88/100	18.4x	92.8%	42.4%	-0.29%	$24.54B	/incy-vs-medp →
IQV IQVIA Holdings Inc.	C-	61/100	33.3x	—	9.4%	-3.32%	$44.06B	/iqv-vs-medp →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001668397 ↗

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Medpace Holdings Inc. (MEDP) reported GAAP revenue of $2.53B (+20.0% vs. FY2024 revenue of $2.11B , and +34.2% cumulative change since FY2023) , GAAP net income of $451.1M, operating cash flow of $713.2M, and free cash flow of $681.9M (+19.2% YoY). On the balance sheet, MEDP closed FY2025 with $1.98B in total assets against $682.4M in total debt (Altman Z-Score: 9.13, Piotroski F-Score: 7/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$2.53B	$451.1M	$713.2M	$681.9M	$1.98B	$682.4M
FY2024 (FY)	2024-12-31	$2.11B	$404.4M	$608.8M	$572.3M	$2.10B	$573.9M
FY2023 (FY)	2023-12-31	$1.89B	$282.8M	$433.4M	$348.5M	$10.42B	$2.44B

3. MEDP Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is MEDP stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

How does MEDP compare to CRL and ICLR in the Health Care sector?

What are the biggest fundamental strengths and SEC risk factors for MEDP?

Where is MEDP trading relative to its 50-day, 200-day, and 52-week technical levels?

MEDP last traded at $648.14 (-0.59% on volume of 198,877 shares), positioning the stock +4.17% above its 50-day simple moving average ($622.17) and +22.23% above its 200-day simple moving average ($530.25). Across its 52-week range of $373.00 to $693.97, MEDP sits at the 85.7% percentile with a 14-day RSI of 52.4 (NEUTRAL RANGE) and an implied next-earnings move of ±7.2% ($601.47 to $694.81).

Direct Sub-Reports: MEDP RQD Cockpit MEDP 12M Forecast MEDP Earnings & Move MEDP Dividends & DRIP MEDP Insiders & 13F MEDP Whale Options MEDP Profit Sankey MEDP News & Why

ROARABLE RATING BRIEF • RQD 77/100 (B+) ✓ SEC XBRL & RQD VERIFIED

MEDP — Medpace Holdings Inc.: What the Facts Mean to a Prospective Investor

Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit

Updated: 2025-12-31

1. Roarable Rating Brief: What This Means to a Prospective Investor

Medpace Holdings Inc. (MEDP) earns a live Roarable RQD composite score of 77/100, corresponding to a B+ letter grade (Roarable Buy) at a spot price of $648.14 (-0.59% 1D, market capitalization $18.24B).

Fundamental Cash Engine (19/20): Anchored by return on invested capital (ROIC) of 27.9%, gross margin of —, operating margin of 21.1%, and free cash flow yield of 3.60%.
Whale 13F & Options Flow (15/20) + Insider Conviction (16/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
Macro Regime Fit (11/20) + Forensic Balance Sheet (16/20): Incorporates a 1.00x equity beta, Altman Z-Score of 9.13, Piotroski F-Score of 7/9, and Debt/Equity of 1.39x.

2. Business Model, Unit Margins & SEC Financial Trajectory

Medpace Holdings Inc. Is a NASDAQ-listed issuer in the Health Care sector, operating in the Biotechnology: Commercial Physical & Biological Research industry. The profile does not describe its specific products, customer base, or revenue model. Market capitalization is listed at $19.0B.

In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-12-31), Medpace Holdings Inc. (MEDP) reported $2.53B in annual revenue (up from $2.11B in FY2024, +20.0% YoY) and $451.1M in GAAP net income. Over the multi-year SEC filing window from FY2023 ($1.89B revenue, $282.8M net income) through FY2025, MEDP scaled operating cash flow to $713.2M and free cash flow to $681.9M, backed by $1.98B in total assets against $682.4M in total debt.

3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff

🐂 Primary Bull Case (B+ • RQD 77/100): Strong cash generator (steady margins)—profits are backed by real money, not accounting tricks. Big institutional funds and options desks are actively positioning on the bullish side. With Fundamental Cash Engine at 19/20 and Institutional Whale Flow at 15/20, sustained execution supports upside toward the upper end of the $373.00 – $693.97 52-week range.
🐻 Primary Bear Case & Valuation Risk: Priced at 42x earnings—high expectations leave less room for a lukewarm quarter. Investors must weigh 42.0x trailing P/E and 34.0x EV/EBITDA against 21.1% operating margins and a 1.00x macro beta.

4. 2nd-Order Butterfly Ripples & Key Questions to Watch

The source therefore does not map upstream suppliers, downstream customers, or sector correlations beyond the sector and industry labels. A prospective investor should note that second-order exposure cannot be assessed from this dataset.

Key Question #1: Can MEDP sustain or expand its 21.1% operating margin and 27.9% ROIC against Biotechnology: Commercial Physical & Biological Resarch peers over the next 4 quarters?
Key Question #2: Following FY2025 revenue of $2.53B and free cash flow of $681.9M, how will capital allocation balance growth reinvestment against $682.4M in total debt?
Key Question #3: How sensitive is MEDP's 35.3x forward P/E multiple to Health Care capital spending cycles and macro interest-rate shifts (Beta 1.00x)?

MEDP Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Medpace Holdings Inc. (MEDP) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to MEDP Debate Forum (3) ↓

🟡 MARKET WIRE Yahoo! Finance Canada • 22h ago

Medpace Holdings, Inc. (MEDP) Stock Price, News, Quote & History

Yahoo! Finance Canada report covering Medpace Holdings Inc. (MEDP) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🔴 RISK WATCH Investor's Business Daily • 1d ago

Medpace Slumps On Solid Report — Where Are The 'Holes?'

Investor's Business Daily report covering Medpace Holdings Inc. (MEDP) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Benzinga • 1d ago

Here’s How Much You Would Have Made Owning Medpace Holdings Stock In The Last 10 Years

Benzinga report covering Medpace Holdings Inc. (MEDP) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟢 CATALYST Seeking Alpha • 1d ago

Medpace: Strong Execution Faces A High-Growth Bar (NASDAQ:MEDP)

Seeking Alpha report covering Medpace Holdings Inc. (MEDP) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Yahoo Finance UK • 1d ago

Medpace (MEDP) Stock Declines While Market Improves: Some Information for Investors

Yahoo Finance UK report covering Medpace Holdings Inc. (MEDP) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE TradingView • 1d ago

Medpace (NASDAQ:MEDP) reports Q3 2026 in line with expectations

TradingView report covering Medpace Holdings Inc. (MEDP) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Seeking Alpha • 1d ago

Medpace: A Shorter, Cleaner Backlog Is Being Mistaken For A Smaller One (NASDAQ:MEDP)

Seeking Alpha report covering Medpace Holdings Inc. (MEDP) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Yahoo Finance • 1d ago

What To Expect From Medpace’s (MEDP) Q3 Earnings

Yahoo Finance report covering Medpace Holdings Inc. (MEDP) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

MEDP Bull vs. Bear Conversation Board — What's Your Call at $648.14?

🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON MEDP 🐻 33% BEARISH CONVICTION

CA CashFlowKing RQD DEBATE OPENER • FCF Compounder Hunter 🐂 BULLISH 🎯 Target: $808.49 (+24.0%)

📌 Pinned Debate

Revenue grew from $1.89B to $2.53B with ROIC of 27.9%, supported by an Altman Z-Score of 9.13 and a 2025 FCF of $681.9M.

Here is why I am bullish on MEDP here at $652.01: Revenue grew from $1.89B to $2.53B with ROIC of 27.9%, supported by an Altman Z-Score of 9.13 and a 2025 FCF of $681.9M.. Compare MEDP's 21.1% operating margin and 27.9% ROIC against the rest of Biotechnology: Commercial Physical & Biological Resarch. As long as cash conversion holds up, dips toward $619.41 are getting bought.

CapAlloc_Nerd 🐂 BULL

@CashFlowKing Agree on the RQD 77/100 quality, though with 1.0 beta I'm scaling in with half-size at $652.01 and keeping dry powder in case we test $606.37.

FA FadeTheHype RQD DEBATE OPENER • Contrarian Tape Reader 🐻 BEARISH 🎯 Target: $495.53 (-24.0%)

Spot @ $652.01

A trailing P/E of 42 and EV/EBITDA of 34 with a 3.6% FCF yield leave the valuation dependent on sustained growth, and the stock is at $

A trailing P/E of 42 and EV/EBITDA of 34 with a 3.6% FCF yield leave the valuation dependent on sustained growth, and the stock is at $677.56 near its $693.97 52-week high.. Look at the math on MEDP: paying 42.0x trailing P/E for 27.9% ROIC and 21.1% operating margins leaves zero margin of safety if Biotechnology: Commercial Physical & Biological Resarch demand softens. I'd wait for a retest of $573.77 before getting long.